January 18, 2022

Illicit Covid-19 Drugs Bound for Mexico Seized by U.S. Authorities

Federal authorities have seized at U.S. airports unauthorized versions of the Covid-19 treatment remdesivir destined for distribution in Mexico, the latest effort by the government to root out criminal activity related to the pandemic.

Counterfeit or generic versions of remdesivir, an antiviral manufactured by

Gilead Sciences Inc.,

GILD -0.45%

are arriving in the U.S. by plane from Bangladesh and India and being smuggled by individuals to Mexico for patients willing to pay top dollar for the drugs, people familiar with the investigation said.

In recent months, U.S. Customs and Border Protection officers have captured more than 100 shipments that they referred to U.S. Department of Homeland Security special agents for further investigation, according to the people.

DHS agents have coordinated testing to determine whether the confiscated items are counterfeit or generic, according to the people. Generic forms of remdesivir aren’t licensed for use in the U.S. or Mexico. In most circumstances, it is illegal in the U.S. to market or import unlicensed prescription drugs.

Counterfeit prescription drugs typically include fraudulent labeling on a container, with another drug or simply water or a saline solution inside, according to industry and security experts. The counterfeit prescription drug market is valued at more than $200 billion annually, according to PricewaterhouseCoopers.

Demand is high for Gilead’s remdesivir in Mexico because the country only recently cleared its use, the people familiar with the matter said. Mexican health officials and the attorney general’s office didn’t respond to requests for comment.

The U.S. Department of Homeland Security, based in Fairfax, Va., is investigating vaccine fraud.


Gabriella Demczuk for The Wall Street Journal

Remdesivir, first cleared by U.S. regulators last year as the pandemic got under way, has shown to provide only a modest benefit. But demand has grown in some countries as the drug has become part of the standard of care in hospitalized patients, largely because of the limited arsenal of tools available to physicians to treat Covid-19 patients.

Authorities outside the U.S. have been investigating counterfeit or unlicensed remdesivir for months. Colombian authorities in January seized containers of a generic version of remdesivir from a woman at an airport who said the drugs were a Covid-19 vaccine, local officials said. Indian authorities said they arrested a handful of people in connection with counterfeit remdesivir in raids in April and May; in one case, suspects changed the labels and packaging of an antibiotic.

“You’ve got to remember, if you don’t have ready access to a vaccine and your healthcare system is at risk of collapse, you will try anything,” said Shabbir Safdar, executive director of Partnership for Safe Medicines, a U.S. nonprofit group whose members include pharmacist and drug-industry trade groups.

He said that people outside the U.S. will sometimes engage in so-called brown-bagging, in which they purchase prescription medicines on the street and ask doctors to administer the drugs.

“With the potential for Covid to be fatal, people are like, ‘Yeah I’ll go buy remdesivir if I can find it and bring it into the hospital,’ ” he said.

As Covid-19 vaccines roll out in several countries, counterfeits are being marketed online. WSJ explains how phony vaccines end up on the internet and the risks for people who buy them. Illustration: Crystal Tai

Foster City, Calif.-based Gilead said it works with law-enforcement agencies around the world to address threats that counterfeit and substandard pharmaceutical products pose to patients, including investigations involving remdesivir.

“We caution against sourcing Gilead medicine from outside the approved and regulated supply chain, hospitals or pharmacies and will continue to support U.S. law enforcement in taking appropriate actions to protect patients,” the company said.

Over the past three years, law enforcement world-wide detained nearly $12 billion of illegally smuggled medicines, according to the Pharmaceutical Security Institute, a trade group.

For more than a year, the U.S. government has been investigating fraud related to the Covid-19 pandemic, recovering phony masks, personal protective equipment and other products. It is also working with pharmaceutical companies on investigations related to their Covid-19 products, including counterfeit shots of the Covid-19 vaccine from

Pfizer Inc.

PFE 0.48%


BioNTech SE.

BNTX 4.60%

Remdesivir was authorized for emergency use by the U.S. Food and Drug Administration last spring and received full approval in October 2020. The intravenous drug is sold under the brand name Veklury and carries a U.S. list price of $520 a vial, or $3,120 for a typical course of treatment. The U.S. government and other developed countries can buy a vial for $390.

In the U.S. investigation, CBP officers have seized boxes of products in Texas and New York flown in from India and Bangladesh, according to the people familiar with the investigation.

The items seized mostly come in 10-vial packages under generic names, and not Veklury, and they are labeled as doctor samples or testing kits, according to the people. They say the drugs are being shipped in packages, and not carried by passengers, and are then smuggled by individuals into Mexico.

No arrests have been made, and more details were unavailable because the investigation is ongoing, the people said.

Companies in India, Egypt and Pakistan are manufacturing generic forms of remdesivir, after Gilead last year agreed to license production through a program that the company says has enabled more than 2.3 million people in more than 60 developing countries to use the drugs. Gilead has licensed generic versions of its product to be distributed in more than 100 countries.

Mexican regulators authorized the drug’s use in treating Covid-19 patients in March. U.S. authorities have seen generic forms of remdesivir for sale in Mexico, the people said.

Under Mexico’s authorization, state governments may purchase Veklury and patients can access the drug through local government healthcare providers, a company spokesman said. He said that Gilead hopes to gain full approval, which would expand supply to the private sector.

Some companies in Hungary, Russia and Bangladesh have produced generic copies of the Gilead drug without licensing from the company, including through compulsory licenses granted by their governments. Countries can grant such licenses to drugmakers, allowing them to copy a company’s patented drugs without its approval, under international rules of the World Trade Organization.

Gilead declined to comment or verify the authenticity or effectiveness of such products. It also declined to comment on whether any were involved in alleged smuggling operations.

Covid-19 Vaccines and Crime

More WSJ coverage of pandemic-related criminal activity, selected by the editors

Write to Jared S. Hopkins at jared.hopkins@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Trump Organization CFO Allen Weisselberg Surrenders to Authorities

July 1, 2021

July 1, 2021

The Trump Organization’s finance chief Allen Weisselberg surrendered to New York prosecutors Thursday morning as he and the company’s lawyers...

Tesla Recalls Over 285,000 Vehicles in China, Most of Them Locally Made

June 26, 2021

June 26, 2021

Tesla Inc. TSLA -1.17% is recalling more than 285,000 passenger vehicles in China—including more than 90% of locally made vehicles...

Uber, Lyft Sweeten Job Perks Amid Driver Shortage, Lofty Fares

July 2, 2021

July 2, 2021

A shortage of drivers in the U.S. is propelling prices for Uber and Lyft LYFT 0.58% rides to record highs...

Regeneron’s Antibody Drug Cuts Risk of Death in Some Covid-19 Patients

June 16, 2021

June 16, 2021

An antibody treatment developed by Regeneron Pharmaceuticals Inc. REGN -0.24% has been shown to significantly cut the risk of death...

Medline Deal Signals Return to Days of Huge Leveraged Buyouts

June 6, 2021

June 6, 2021

Blackstone Group Inc., BX 1.29% Carlyle Group Inc. and Hellman & Friedman LLC said Saturday they struck a buyout deal...

Toshiba Shareholders Oust Chairman in Landmark for Foreign Activists

June 25, 2021

June 25, 2021

TOKYO— Toshiba Corp.’s TOSYY 0.18% chairman was ousted in a vote at the company’s annual meeting, a milestone in Japanese...

The Economic Recovery Is Here. It’s Unlike Anything You’ve Seen.

June 2, 2021

June 2, 2021

The U.S. economic recovery is unlike any in recent history, powered by consumers with trillions in extra savings, businesses eager...

Bitcoin on the Balance Sheet Is an Accounting Headache for Tesla, Others

June 14, 2021

June 14, 2021

Elon Musk’s curious Twitter war with bitcoin is expected to hit Tesla Inc.’s TSLA -0.04% bottom line this quarter. Mr....

The Rise and Fall of Teneo’s Declan Kelly

July 2, 2021

July 2, 2021

The pitch was the same. You need me. You can’t trust your people. I can fix this. And it was...

Major Internet Outage Shuts Down News, Government Websites

June 8, 2021

June 8, 2021

Dozens of websites in the U.S. and Europe were inaccessible early Tuesday, with at least one internet outage tracker reporting...

Tesla to Store China Data Locally in New Data Center

May 26, 2021

May 26, 2021

SHANGHAI— Tesla Inc. TSLA -0.29% said all data generated from cars it sold in China will be stored in a...

Activist Wins Exxon Board Seats After Questioning Oil Giant’s Climate Strategy

May 26, 2021

May 26, 2021

An activist investor won at least two seats on the board of Exxon Mobil Corp. XOM 1.24% , a historic...

WarnerMedia CEO Jason Kilar Says He Will Stay at Company at Least Through 2021

May 27, 2021

May 27, 2021

WarnerMedia Chief Executive Jason Kilar said in a companywide address Thursday that he has no plans to step down this...

SEC’s Gary Gensler Speaks at WSJ Event

June 7, 2021

June 7, 2021

Watch U.S. Securities and Exchange Commission Chairman Gary Gensler in an interview with WSJ’s Jean Eaglesham. Gary Gensler, chairman of...

Covid-19 Testing Could Be a Viable Long-Term Business Bet

June 6, 2021

June 6, 2021

With slow vaccination rates threatening the likelihood of herd immunity, companies and federal and state governments are pouring billions of...